Muscular  ||| S:0 E:9 ||| JJ
microRNA  ||| S:9 E:18 ||| JJ
expressions  ||| S:18 E:30 ||| NNS
in  ||| S:30 E:33 ||| IN
healthy  ||| S:33 E:41 ||| JJ
and  ||| S:41 E:45 ||| CC
myopathic  ||| S:45 E:55 ||| JJ
horses  ||| S:55 E:62 ||| NNS
suffering  ||| S:62 E:72 ||| VBG
from  ||| S:72 E:77 ||| IN
polysaccharide  ||| S:77 E:92 ||| JJ
storage  ||| S:92 E:100 ||| NN
myopathy  ||| S:100 E:109 ||| NNS
or  ||| S:109 E:112 ||| CC
recurrent  ||| S:112 E:122 ||| FW
exertional  ||| S:122 E:133 ||| FW
rhabdomyolysis  ||| S:133 E:148 ||| FW
MicroRNAs  ||| S:148 E:158 ||| FW
( ||| S:158 E:159 ||| -LRB-
miRNA ||| S:159 E:164 ||| NNP
)  ||| S:164 E:166 ||| -RRB-
are  ||| S:166 E:170 ||| VBP
small  ||| S:170 E:176 ||| JJ
endogenous  ||| S:176 E:187 ||| FW
noncoding  ||| S:187 E:197 ||| FW
interfering  ||| S:197 E:209 ||| FW
RNA  ||| S:209 E:213 ||| FW
molecules  ||| S:213 E:223 ||| FW
( ||| S:223 E:224 ||| -LRB-
18-25  ||| S:224 E:230 ||| FW
nucleotides ||| S:230 E:241 ||| FW
)  ||| S:241 E:243 ||| -RRB-
regarded  ||| S:243 E:252 ||| VBN
as  ||| S:252 E:255 ||| IN
major  ||| S:255 E:261 ||| JJ
regulators  ||| S:261 E:272 ||| NNS
in  ||| S:272 E:275 ||| IN
eukaryotic  ||| S:275 E:286 ||| JJ
gene  ||| S:286 E:291 ||| NN
expression ||| S:291 E:301 ||| NN
.  ||| S:301 E:303 ||| .
They  ||| S:303 E:308 ||| PRP
play  ||| S:308 E:313 ||| VBP
a  ||| S:313 E:315 ||| DT
role  ||| S:315 E:320 ||| NN
in  ||| S:320 E:323 ||| IN
developmental  ||| S:323 E:337 ||| JJ
timing ||| S:337 E:343 ||| NN
,  ||| S:343 E:345 ||| ,
cellular  ||| S:345 E:354 ||| JJ
differentiation ||| S:354 E:369 ||| NN
,  ||| S:369 E:371 ||| ,
signalling  ||| S:371 E:382 ||| VBG
and  ||| S:382 E:386 ||| CC
apoptosis  ||| S:386 E:396 ||| JJ
pathways ||| S:396 E:404 ||| NN
.  ||| S:404 E:406 ||| .
Because  ||| S:406 E:414 ||| IN
of  ||| S:414 E:417 ||| IN
the  ||| S:417 E:421 ||| DT
central  ||| S:421 E:429 ||| JJ
function  ||| S:429 E:438 ||| NN
of  ||| S:438 E:441 ||| IN
miRNAs  ||| S:441 E:448 ||| JJ
in  ||| S:448 E:451 ||| IN
the  ||| S:451 E:455 ||| DT
proliferation  ||| S:455 E:469 ||| NN
and  ||| S:469 E:473 ||| CC
differentiation  ||| S:473 E:489 ||| NN
of  ||| S:489 E:492 ||| IN
the  ||| S:492 E:496 ||| DT
myoblasts  ||| S:496 E:506 ||| NN
demonstrated  ||| S:506 E:519 ||| VBN
in  ||| S:519 E:522 ||| IN
mouse  ||| S:522 E:528 ||| NN
and  ||| S:528 E:532 ||| CC
man ||| S:532 E:535 ||| NN
,  ||| S:535 E:537 ||| ,
it  ||| S:537 E:540 ||| PRP
is  ||| S:540 E:543 ||| VBZ
assumed  ||| S:543 E:551 ||| VBN
that  ||| S:551 E:556 ||| IN
they  ||| S:556 E:561 ||| PRP
could  ||| S:561 E:567 ||| MD
be  ||| S:567 E:570 ||| VB
present  ||| S:570 E:578 ||| JJ
in  ||| S:578 E:581 ||| IN
equine  ||| S:581 E:588 ||| JJ
muscles  ||| S:588 E:596 ||| NNS
and  ||| S:596 E:600 ||| CC
their  ||| S:600 E:606 ||| PRP$
expression  ||| S:606 E:617 ||| NN
profile  ||| S:617 E:625 ||| NN
may  ||| S:625 E:629 ||| MD
be  ||| S:629 E:632 ||| VB
related  ||| S:632 E:640 ||| VBN
to  ||| S:640 E:643 ||| TO
the  ||| S:643 E:647 ||| DT
muscle  ||| S:647 E:654 ||| NN
status ||| S:654 E:660 ||| NN
.  ||| S:660 E:662 ||| .
To  ||| S:662 E:665 ||| TO
identify  ||| S:665 E:674 ||| VB
miRNA  ||| S:674 E:680 ||| JJ
candidates  ||| S:680 E:691 ||| NNS
in  ||| S:691 E:694 ||| IN
the  ||| S:694 E:698 ||| DT
muscles  ||| S:698 E:706 ||| NN
of  ||| S:706 E:709 ||| IN
control  ||| S:709 E:717 ||| NN
and  ||| S:717 E:721 ||| CC
affected  ||| S:721 E:730 ||| JJ
horses  ||| S:730 E:737 ||| NNS
suffering  ||| S:737 E:747 ||| VBG
from  ||| S:747 E:752 ||| IN
polysaccharide  ||| S:752 E:767 ||| JJ
storage  ||| S:767 E:775 ||| NN
myopathy  ||| S:775 E:784 ||| NNS
( ||| S:784 E:785 ||| -LRB-
PSSM ||| S:785 E:789 ||| NNP
)  ||| S:789 E:791 ||| -RRB-
and  ||| S:791 E:795 ||| CC
recurrent  ||| S:795 E:805 ||| FW
exertional  ||| S:805 E:816 ||| FW
rhabdomyolysis  ||| S:816 E:831 ||| FW
( ||| S:831 E:832 ||| -LRB-
RER ||| S:832 E:835 ||| NNP
) ||| S:835 E:836 ||| -RRB-
.  ||| S:836 E:838 ||| .
Muscle  ||| S:838 E:845 ||| NN
biopsies  ||| S:845 E:854 ||| NNS
were  ||| S:854 E:859 ||| VBD
collected  ||| S:859 E:869 ||| VBN
in  ||| S:869 E:872 ||| IN
the  ||| S:872 E:876 ||| DT
gluteus  ||| S:876 E:884 ||| JJ
medius  ||| S:884 E:891 ||| NN
of  ||| S:891 E:894 ||| IN
horses  ||| S:894 E:901 ||| NNS
allocated  ||| S:901 E:911 ||| VBN
into  ||| S:911 E:916 ||| IN
4  ||| S:916 E:918 ||| CD
groups ||| S:918 E:924 ||| NNS
:  ||| S:924 E:926 ||| :
French  ||| S:926 E:933 ||| NNP
Trotters  ||| S:933 E:942 ||| NNP
( ||| S:942 E:943 ||| -LRB-
3  ||| S:943 E:945 ||| CD
control-TF  ||| S:945 E:956 ||| NN
vs.  ||| S:956 E:960 ||| IN
3  ||| S:960 E:962 ||| CD
RER-TF ||| S:962 E:968 ||| NN
)  ||| S:968 E:970 ||| -RRB-
and  ||| S:970 E:974 ||| CC
Norman  ||| S:974 E:981 ||| NNP
Cob  ||| S:981 E:985 ||| NNP
( ||| S:985 E:986 ||| -LRB-
5  ||| S:986 E:988 ||| CD
control-Cob  ||| S:988 E:1000 ||| NN
vs.  ||| S:1000 E:1004 ||| IN
9  ||| S:1004 E:1006 ||| CD
PSSM-Cob ||| S:1006 E:1014 ||| NN
) ||| S:1014 E:1015 ||| -RRB-
.  ||| S:1015 E:1017 ||| .
Blood  ||| S:1017 E:1023 ||| NN
samples  ||| S:1023 E:1031 ||| NNS
were  ||| S:1031 E:1036 ||| VBD
collected  ||| S:1036 E:1046 ||| VBN
for  ||| S:1046 E:1050 ||| IN
miRNA  ||| S:1050 E:1056 ||| JJ
analysis ||| S:1056 E:1064 ||| NN
.  ||| S:1064 E:1066 ||| .
Total  ||| S:1066 E:1072 ||| JJ
RNA  ||| S:1072 E:1076 ||| NNP
were  ||| S:1076 E:1081 ||| VBD
extracted  ||| S:1081 E:1091 ||| VBN
and  ||| S:1091 E:1095 ||| CC
real  ||| S:1095 E:1100 ||| JJ
time  ||| S:1100 E:1105 ||| NN
quantitative  ||| S:1105 E:1118 ||| JJ
RT-QPCR  ||| S:1118 E:1126 ||| JJ
analysis  ||| S:1126 E:1135 ||| NN
were  ||| S:1135 E:1140 ||| VBD
conducted  ||| S:1140 E:1150 ||| VBN
using  ||| S:1150 E:1156 ||| VBG
10  ||| S:1156 E:1159 ||| CD
miRNA  ||| S:1159 E:1165 ||| JJ
assays  ||| S:1165 E:1172 ||| NNS
( ||| S:1172 E:1173 ||| -LRB-
mir-1-23-30-133-181-188-195-206-339-375 ||| S:1173 E:1212 ||| NNP
) ||| S:1212 E:1213 ||| -RRB-
.  ||| S:1213 E:1215 ||| .
All  ||| S:1215 E:1219 ||| PDT
the  ||| S:1219 E:1223 ||| DT
miRNA  ||| S:1223 E:1229 ||| JJ
candidates  ||| S:1229 E:1240 ||| NNS
were  ||| S:1240 E:1245 ||| VBD
significantly  ||| S:1245 E:1259 ||| RB
detected  ||| S:1259 E:1268 ||| VBN
in  ||| S:1268 E:1271 ||| IN
the  ||| S:1271 E:1275 ||| DT
muscles  ||| S:1275 E:1283 ||| NNS
and  ||| S:1283 E:1287 ||| CC
some  ||| S:1287 E:1292 ||| DT
in  ||| S:1292 E:1295 ||| IN
blood  ||| S:1295 E:1301 ||| NN
samples ||| S:1301 E:1308 ||| NNS
.  ||| S:1308 E:1310 ||| .
Variance  ||| S:1310 E:1319 ||| JJ
analysis  ||| S:1319 E:1328 ||| NN
revealed  ||| S:1328 E:1337 ||| VBD
highly  ||| S:1337 E:1344 ||| RB
significant  ||| S:1344 E:1356 ||| JJ
( ||| S:1356 E:1357 ||| -LRB-
P  ||| S:1357 E:1359 ||| NNP
< ||| S:1359 E:1361 ||| SYM
0.0001 ||| S:1361 E:1367 ||| NNP
)  ||| S:1367 E:1369 ||| -RRB-
effects  ||| S:1369 E:1377 ||| NNS
of  ||| S:1377 E:1380 ||| IN
the  ||| S:1380 E:1384 ||| DT
miRNA  ||| S:1384 E:1390 ||| JJ
type ||| S:1390 E:1394 ||| NN
,  ||| S:1394 E:1396 ||| ,
breed  ||| S:1396 E:1402 ||| NN
and  ||| S:1402 E:1406 ||| CC
pathology  ||| S:1406 E:1416 ||| NN
on  ||| S:1416 E:1419 ||| IN
the  ||| S:1419 E:1423 ||| DT
miRNA  ||| S:1423 E:1429 ||| JJ
expression ||| S:1429 E:1439 ||| NN
.  ||| S:1439 E:1441 ||| .
A  ||| S:1441 E:1443 ||| DT
specific  ||| S:1443 E:1452 ||| JJ
miRNA  ||| S:1452 E:1458 ||| JJ
profile  ||| S:1458 E:1466 ||| NN
was  ||| S:1466 E:1470 ||| VBD
related  ||| S:1470 E:1478 ||| VBN
to  ||| S:1478 E:1481 ||| TO
each  ||| S:1481 E:1486 ||| DT
myopathy ||| S:1486 E:1494 ||| NN
:  ||| S:1494 E:1496 ||| :
a  ||| S:1496 E:1498 ||| DT
higher  ||| S:1498 E:1505 ||| JJR
expression  ||| S:1505 E:1516 ||| NN
of  ||| S:1516 E:1519 ||| IN
mir-1 ||| S:1519 E:1524 ||| NNP
,  ||| S:1524 E:1526 ||| ,
133 ||| S:1526 E:1529 ||| CD
,  ||| S:1529 E:1531 ||| ,
23a ||| S:1531 E:1534 ||| NNP
,  ||| S:1534 E:1536 ||| ,
30b ||| S:1536 E:1539 ||| NNP
,  ||| S:1539 E:1541 ||| ,
195  ||| S:1541 E:1545 ||| CD
and  ||| S:1545 E:1549 ||| CC
339  ||| S:1549 E:1553 ||| CD
in  ||| S:1553 E:1556 ||| IN
RER-TF  ||| S:1556 E:1563 ||| FW
vs.  ||| S:1563 E:1567 ||| FW
control-TF  ||| S:1567 E:1578 ||| FW
( ||| S:1578 E:1579 ||| -LRB-
P  ||| S:1579 E:1581 ||| NNP
< ||| S:1581 E:1583 ||| SYM
0.05 ||| S:1583 E:1587 ||| CD
) ||| S:1587 E:1588 ||| -RRB-
;  ||| S:1588 E:1590 ||| :
a  ||| S:1590 E:1592 ||| DT
higher  ||| S:1592 E:1599 ||| JJR
expression  ||| S:1599 E:1610 ||| NN
of  ||| S:1610 E:1613 ||| IN
mir-195  ||| S:1613 E:1621 ||| CD
in  ||| S:1621 E:1624 ||| IN
PSSM-Cob  ||| S:1624 E:1633 ||| FW
vs.  ||| S:1633 E:1637 ||| FW
control-Cob  ||| S:1637 E:1649 ||| FW
( ||| S:1649 E:1650 ||| -LRB-
P  ||| S:1650 E:1652 ||| NNP
< ||| S:1652 E:1654 ||| SYM
0.05 ||| S:1654 E:1658 ||| CD
) ||| S:1658 E:1659 ||| -RRB-
.  ||| S:1659 E:1661 ||| .
The  ||| S:1661 E:1665 ||| DT
miRNA  ||| S:1665 E:1671 ||| JJ
profile  ||| S:1671 E:1679 ||| NN
was  ||| S:1679 E:1683 ||| VBD
different  ||| S:1683 E:1693 ||| JJ
between  ||| S:1693 E:1701 ||| IN
breeds  ||| S:1701 E:1708 ||| NN
for  ||| S:1708 E:1712 ||| IN
mir-181 ||| S:1712 E:1719 ||| NNP
,  ||| S:1719 E:1721 ||| ,
188  ||| S:1721 E:1725 ||| CD
and  ||| S:1725 E:1729 ||| CC
206  ||| S:1729 E:1733 ||| CD
( ||| S:1733 E:1734 ||| -LRB-
P  ||| S:1734 E:1736 ||| NNP
< ||| S:1736 E:1738 ||| SYM
0.05 ||| S:1738 E:1742 ||| CD
) ||| S:1742 E:1743 ||| -RRB-
.  ||| S:1743 E:1745 ||| .
The  ||| S:1745 E:1749 ||| DT
mir-1 ||| S:1749 E:1754 ||| NNP
,  ||| S:1754 E:1756 ||| ,
133 ||| S:1756 E:1759 ||| CD
,  ||| S:1759 E:1761 ||| ,
181 ||| S:1761 E:1764 ||| CD
,  ||| S:1764 E:1766 ||| ,
195  ||| S:1766 E:1770 ||| CD
and  ||| S:1770 E:1774 ||| CC
206  ||| S:1774 E:1778 ||| CD
were  ||| S:1778 E:1783 ||| VBD
detected  ||| S:1783 E:1792 ||| VBN
in  ||| S:1792 E:1795 ||| IN
blood  ||| S:1795 E:1801 ||| NN
of  ||| S:1801 E:1804 ||| IN
control-Cob  ||| S:1804 E:1816 ||| JJ
and  ||| S:1816 E:1820 ||| CC
PSSM-Cob  ||| S:1820 E:1829 ||| JJ
horses ||| S:1829 E:1835 ||| NNS
.  ||| S:1835 E:1837 ||| .
This  ||| S:1837 E:1842 ||| DT
first  ||| S:1842 E:1848 ||| JJ
study  ||| S:1848 E:1854 ||| NN
about  ||| S:1854 E:1860 ||| IN
muscular  ||| S:1860 E:1869 ||| JJ
miRNA  ||| S:1869 E:1875 ||| JJ
profile  ||| S:1875 E:1883 ||| NN
in  ||| S:1883 E:1886 ||| IN
equine  ||| S:1886 E:1893 ||| JJ
myopathies  ||| S:1893 E:1904 ||| NN
indicated  ||| S:1904 E:1914 ||| VBD
that  ||| S:1914 E:1919 ||| IN
it  ||| S:1919 E:1922 ||| PRP
is  ||| S:1922 E:1925 ||| VBZ
possible  ||| S:1925 E:1934 ||| JJ
to  ||| S:1934 E:1937 ||| TO
discriminate  ||| S:1937 E:1950 ||| VB
pathological  ||| S:1950 E:1963 ||| VBN
from  ||| S:1963 E:1968 ||| IN
control  ||| S:1968 E:1976 ||| NN
horses  ||| S:1976 E:1983 ||| NNS
according  ||| S:1983 E:1993 ||| VBG
to  ||| S:1993 E:1996 ||| TO
their  ||| S:1996 E:2002 ||| PRP$
miRNA  ||| S:2002 E:2008 ||| JJ
profile ||| S:2008 E:2015 ||| NN
.  ||| S:2015 E:2017 ||| .
The  ||| S:2017 E:2021 ||| DT
RER  ||| S:2021 E:2025 ||| NNP
miRNA  ||| S:2025 E:2031 ||| JJ
profile  ||| S:2031 E:2039 ||| NN
was  ||| S:2039 E:2043 ||| VBD
more  ||| S:2043 E:2048 ||| RBR
specific  ||| S:2048 E:2057 ||| JJ
and  ||| S:2057 E:2061 ||| CC
contrasted  ||| S:2061 E:2072 ||| VBN
than  ||| S:2072 E:2077 ||| IN
the  ||| S:2077 E:2081 ||| DT
PSSM  ||| S:2081 E:2086 ||| NNP
profile ||| S:2086 E:2093 ||| NN
.  ||| S:2093 E:2095 ||| .
